

NASDAQ: CEMI







Investor Presentation

March 2014

Forward-Looking Statements

Statements contained herein that are not historical facts are forwardlooking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to develop, manufacture, market and finance new products and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Other factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.



Investment Summary



- Develops, Manufactures & Markets Point-of-Care Diagnostic Tests (POCTs)
 - Global Sales Direct and Through Partnerships
 - \$8B Global Market with Current Pipeline Addressing \$650MM Segment
- Five Consecutive Years of Profitability & Revenue Growth
 - 2013 Revenues and Product Gross Margin Increased by 15% and 8% respectively vs. 2012
- Patented DPP[®] A Platform POCT Technology
 - Uniquely Enables Multiplexing for Higher Value Tests & Increased Sensitivity
 - DPP[®] Oral Fluid HIV Test FDA-Approved CLIA waiver pending
 - DPP[®] HIV-Syphilis Test Strong outlook for international sales in 2014
- Pipeline of DPP[®] POCT Products
 - DPP[®] HCV Ab & HIV Ag-Ab Test



Our Vision & Mission



We are a provider of Point-of-Care diagnostic tests and solutions, helping people live longer and healthier lives.

Our Mission is to become a key provider in the market for rapid diagnostic Point of Care (POC) testing, through the development, manufacture, and commercialization of proprietary technology with superior performance and technical service.





Chembio Products are well Positioned Globally for Growth...

USA

- Distribution through Alere (30% FY13 revenue)
- DPP[®] HIV PMA approval (Dec'12) / CLIA pending
- Funded Research Collaborations with CDC, DOD, NIH (6% FY13)

EU

- CE mark approval for SURECHECK[®] (July'13)
- CE mark for STATPAK[®], DPP[®] HIV HIV/Syphilis pending



ASIA

AFRICA

- Procurements primarily funded by PEPFAR, Global Fund, and WHO
- Sales channel ; NGO-direct & through distributors (14% FY13 revenue)
- Commercial resource deployment




SOUTH/CENTRAL AMERICA

 Strong OEM Partnerships (FIOCRUZ, Labtest); Branded products sold to NGOs, private distributors (45% FY13)

POCTs - A Growing \$8B Global Market

Long-term Trend Toward Molecular Levels of Detection






Chembio's Lateral Flow Rapid HIV Tests Marketed World-Wide

• Total \$20.2MM FY 2013

- 50% Increase vs. FY2012
- 5-8.5% Royalties Ending Feb. 2015
- In U.S. Market Sold Exclusively through Alere
 - \$8.9MM in FY 2013
 - 14% Increase vs. FY2012
 - Possibility to Sell Direct in 2014
- International Market Sold Through Multiple Channels
 - \$11.8MM in FY2013
 - 84.5% Increase vs. FY2012



Chembio SURE CHECK[®] HIV 1/2 Alere Clearview Complete[®] HIV 1/2



Chembio HIV 1/2 STAT-PAK [®] Alere Clearview HIV 1/2 STAT-PAK[®]



Chembio's Dual Path Platform (DPP[®]) Patented Point-of-Care Test Technology

- Proprietary Platform Technology that Uniquely Enables Multiplexing for Higher Value Tests
- Increases Sensitivity as Compared with Lateral Flow Technology
- Validated with Numerous Partners, Regulatory Agencies
- New DPP[®] Patents Issued in 2013



Chembio's Pipeline: \$650MM Total Addressable Market

Chembio Pipeline POCT	Total Estimated Market Opportunity	Targeted Launch
HIV POCT - U.S.	\$75 MM	\$8.9MM Product Sales 2013 ; New Oral Fluid Product Launch 2014
HIV-Syphilis - U.S.	\$75 MM	2015
Hepatitis C POCT – U.S.	\$100 MM	2016
Combined Estimated Market for Above – ex-U.S.	\$400 MM	\$27.5MM Product Sales in FY2013 Significant Growth Opportunities with Current and New Products

Total:

\$650 MM



Chembio POCT Market Opportunities: HIV Rapid POCTS


Established, Growing Markets

U.S.

- ~50,000 New Infections in 2012
- USPSTF Recommends Routine Testing
 - ACA Expanding Coverage by 25MM+

International

- 2.5 MM New Infections Worldwide in 2012
- Designation in PEPFAR & Other Donor-Funded Countries' Testing Protocols





Chembio DPP[®] HIV 1/2 Assay FDA-Approved Dec. '12 CLIA Waiver Application Filed with FDA , November 2013 Anticipated Launch in 2014

- Build on Established Position/Performance of Our FDA Lateral Flow Products with Only Alternative to Current ~\$35MM Oral Fluid Product
- Superior Blood Matrix Performance over Top 4 Market Share Products in Early Detection Study
- Superior Oral Fluid Sensitivity v. Market Leader in Only Head-to-Head Study
- User Friendly, Safe and Efficient SampleTainer[™] Sample Collection System
- Separate and Reagent-Free Oral Fluid Collection Device





DPP® HIV-Syphilis Multiplex Assay

- Large Global Market Opportunities for Pre-Natal and MSM Screening
- Higher Prevalence of Syphilis (1.9MM) than HIV (1.5MM) in Pregnant Women
- International & US Regulatory Approval and Commercialization Efforts Underway
- Up to 70% HIV-Syphilis Co-Infection in MSM
 - First Such Test to be USAID-approved
 - Strong Start and Outlook 2014
 - Anticipate FDA PMA Submission in 2014



OEM & License Agreements Expanding Relationships and Sales Opportunities

Oswaldo Cruz Foundation

- Five DPP[®] Products , ~\$6MM 2013 revenues
- Brazilian MOH Supplier
- Collaboration with LabTest Brazil
 - Assembly & Distribution DPP[®] Co-branded
 - 2014 Plan = Initial Products Registrations
- Agreement with RVR Malaysia
 - License, Distribution, Tech. Transfer and Contract Manufacturing
- **Bio-Rad Laboratories**
 - Exclusive Licensee for DPP[®] HIV Confirmatory Application
 - CE Marked 2013, FDA Pending



Commercial Strategy: Top Line Growth (Sales)

Build a Sales & Marketing Organization to Increase Our Revenue and Maximize Profits

Move up Value Stream in US Diagnostics Market "USA Direct" for Certain Products

Tactic

#1



#3 Maximize Opportunities in Developing World Markets

Tactic



Additional Priorities & Areas of Focus: Technology

Technology Investment


- New Product Launch (DPP HIV/SYP)
- Develop New Technologies (HIV 4G, HCV) that Address Healthcare Concerns
- Identify Additional Technologies to License/Acquire that will Complement our Commercial Strategy





Organization & Facility


- FDA- and USDA-Approved Development & Manufacturing Facility
- All Company Operations in 30,600 Sq. Ft. Leased Facility in Medford, NY



TOTAL EMPLOYMENT: Approximately 200



Selected Financial Data FY2009 –2013





FY2011-2013 - Selected Financial Results

For The Years Ended (in 000's)	De	c 31, 2013		De	c 31, 2012		De	ec 31, 2011
Net Product Revenues	\$	27,516		\$	24,327		\$	17,422
Non-Product Revenues		2,034			1,283			1,966
TOTAL REVENUES		29,550			25,610			19,388
GROSS MARGIN		12,300	42%		10,790	42%		9,390
OPERATING COSTS:								
Research and development exp.		5,834	20%		4,486	18%		4,878
Selling, general and administrative exp.		5,461	18%		4,852	19%		3,424
		11,295			9,338			8,302
INCOME FROM OPERATIONS		1,005			1,452			1,088
Income tax (benefit) provision		487			509			(5,133)
	\$	531	2%	\$	941	4%	\$	6,209
Diluted earnings (loss) per share	\$	0.06		\$	0.11		\$	0.73
Weighted avg shs outstanding-diluted		8,994,080			8,614,944			8,556,284



CEMI Selected Share & Balance Sheet Data

\$6MM Common Stock Public Offering Closed on April 3, 2013 1.2MM Shares @ \$5.00 per share, \$5.450MM Net Proceeds

in millions except per share and daily volume data			5 1/4		
Ticker Symbol (NASDAQ)	CEMI	(\$ in 000s)	Dec.'13	Dec.'12	
Price 02/28/14	\$3.80	Cash	\$9,650	\$2,952	
52-Week High	\$5.70	Total Current Assets	18,531	4,821	
52-Week Low	\$2.98	Total Assets	24,487	17,335	
Outstanding Shares	9.32				
Market Capitalization	\$35.43	Total Current	4,310	3,378	
Fully Diluted Shares	9.99	Liabilities			
Managements Holdings	1.51	Total Liabilities	4,310	3,460	
Avg. Daily Volume	47.000	Stockholders' Equity	20,177	13,875	
(3 mos. to 2/28/14)	47,000	Total Liabilities & Stockholders' Equity	24,487	17,335	

Options – Mgmt. & Board	Total	Avg. Ex. Price
533K	669K	\$2.70



2013 2014YTD Milestones Achieved

Product Development/Regulatory

- Received FDA PMA Approval of DPP Oral Fluid HIV Test
- Substantially Completed CLIA waiver studies
- Received CE Mark for Sure Check HIV 1/2 Assay
- USAID Approval, Initial Sales of HV-Syphilis Test

Corporate/Operations

- Achieved Fifth Straight Year of Sales Growth and Profitability with Strong Gains in Domestic and International Segments
- Strengthened Balance Sheet with Common Stock Issuance, Establishing Institutional Shareholder Base
- Increased Production Capacity to Meet Sales Growth

Commercialization

- Entered International Assembly & Distribution Agreement w/Labtest of Brazil
- Established Distribution, License, Tech. Transfer, Contract Manufacturer in Asia
- Initial International Registrations for HIV-Syphilis ; Receiving Significant Initial Orders



Anticipated Milestones - 2014

Product Development/Regulatory

- Oral Fluid HIV Test CLIA Waiver & Launch
- CE Marks for HIV 1/2 STAT-PAK[®], DPP[®] HIV & HIV-Syphilis Products
- International Sales Growth of DPP [®] HIV-Syphilis Test
- FDA Submission & Approval of DPP[®] HIV-Syphilis Test

Corporate/Operations

- Increase Production Capacity
- Pursue Acquisitions or Licenses of Complementary Products/Technologies
- Announcement of New CEO

Commercialization

- Implement US & International Commercial Strategy, Expand Market and Sales Opportunities
- Expand International Revenues for Lateral Flow and DPP[®] Products
- New Distribution, Contract Development & OEM Deals



Leadership - Executive Team

Executive	Previous Experience	Joined
Lawrence Siebert, J.D. Chairman & CEO	1981-1991, Partner, Stanwich Partners, Inc.; 1992- 2002 Siebert Associates LLC, Manager; Siebert Capital Corp., President	2002
Richard Larkin, CPA Chief Financial Officer	2000-2003 CFO of Visual Technology Group; 1987- 2000 CFO of Protex International Corp.	2003
Sharon Klugewicz, M.S. Chief Operating Officer	20+ Years at Pall Corporation, most recently as Sr. VP - Scientific & Laboratory Services	2012
Javan Esfandiari, M.S. SVP Research & Development	1993-1997, R&D Director On-Site Biotech; 1997-2000, Co-Founder of Sinovus Biotech AB (Sweden), which was acquired by Chembio in 2000	2000
Thomas Ippolito VP Regulatory & Clinical Affairs	25 years experience in the development of vaccines, therapeutics and IVDs working with several major pharmaceutical, vaccine and diagnostic companies	2005
Michael Steele VP Sales Marketing & Bus. Dev.	20-years of business development and strategy execution at life sciences companies Sera Care Life Sciences, Serologicals, Inc. and Corautus Genetics.	2012



Investment Summary



- Develops, Manufactures & Markets Point-of-Care Diagnostic Tests (POCTs)
 - Global Sales Direct and Through Partnerships
 - \$8B Global Market with Current Pipeline Addressing \$650MM Segment
- Five Consecutive Years of Profitability & Revenue Growth
 - 2013 Revenues and Product Gross Margin Increased by 15% and 8% respectively vs. 2012
- Patented DPP[®] A Platform POCT Technology
 - Uniquely Enables Multiplexing for Higher Value Tests & Increased Sensitivity
 - DPP[®] Oral Fluid HIV Test FDA-Approved CLIA waiver pending
 - DPP[®] HIV-Syphilis Test Strong outlook for international sales in 2014
- Pipeline of DPP[®] POCT Products
 - DPP[®] HCV Ab & HIV Ag-Ab Test

